Prevention of Cardiac Disease by Subcutaneous Deferoxamine in Patients with Thalassemia Major

New England Journal of Medicine

Volumn 312, Issue 25, 1985, Pages 1600-1603

  Wolfe, Lawrence ^a,b   Olivieri, Nancy ^a,b   Sallan, Darlene ^a,b   Colan, Steven ^a,b   Rose, Vera ^a,b   Propper, Richard ^a,b   Freedman, Melvin H ^a,b   Nathan, David G ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; ASPARTATE AMINOTRANSFERASE; DEFEROXAMINE; FERRITIN;

BLOOD AND HEMOPOIETIC SYSTEM; CARDIOMYOPATHY; CASE REPORT; CONGESTIVE HEART FAILURE; DRUG THERAPY; HEART; HEART DISEASE; HUMAN; PREVENTION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THALASSEMIA MAJOR; THERAPY;

EID: 0021833690     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198506203122503     Document Type: Article

References (14)

1. Cohen A, Schwartz E. Decreasing iron stores during intensive chelation therapy. Ann NY Acad Sci 1980; 344: 405–17.
2. Propper RD, Cooper B, Rufo RR, et al. Continuous subcutaneous administration of deferoxamine in patients with iron overload. N Engl J Med 1977; 297: 418–23.
3. Barry M, Flynn DM, Letsky EA, Risdon RA. Long-term chelation therapy in thalassaemia major: effect on liver iron concentration, liver histology, and clinical progress. Br Med J 1974; 2: 16–20.
4. Propper R, Clarke D, Nathan DG. Cooley's anemia: the effect of supertransfusion and nightly subcutaneous Desferal on the development of cardiac disease. Blood 1982; 60: Suppl 1: 57A. abstract.
5. Kossmann CE, Chasis H, Foley WT, et al. Diseases of the heart and blood vessels: nomenclature and criteria for diagnosis. 6th ed. Boston: Little, Brown, 1964:110–4.
6. Lown B, Wolf M. Approaches to sudden death from coronary heart disease. Circulation 1971; 44: 130–42.
7. Engle MA. Cardiac involvement in Cooley's anemia. Ann NY Acad Sci 1964; 119: 694–702.
8. Ehlers KH, Levin AR, Markenson AL, et al. Longitudinal study of cardiac function in thalassemia major. Ann NY Acad Sci 1980; 344: 397–404.
9. Hershko C, Link G, Pinson A. Effects of iron loading and chelation on rat myocardial cells in culture. Blood 1984; 64: Suppl 1: 39a. abstract.
10. Freeman AP, Giles RW, Berdoukas VA, Walsh WF, Choy D, Murray PC. Early left ventricular dysfunction and chelation therapy in thalassemia major. Ann Intern Med 1983; 99: 450–4.
11. Marcus RE, Davies SC, Bantock HM, Underwood SR, Walton S, Huehns ER. Desferrioxamine to improve cardiac function in iron-overloaded patients with thalassaemia major. Lancet 1984; 1: 392–3.
12. High dose chelation therapy in thalassaemia. Lancet 1984; 1: 373–4.
13. Modell B, Letsky E, Flynn DM, Peto R. Weatherall DJ. Survival and desferrioxamine in thalassaemia major. Br Med J 1982; 284: 1081–4.
14. Weatherall DJ, Pippard MJ, Callender ST. Iron loading in thalassemia — five years with the pump. N Engl J Med 1983; 308: 456–8.